- Tags: geographic atrophy
Research
Reducing chronic inflammation minimizes AMD-linked vision loss
Mouse model demonstrates role of NLRP3 in AMD pathology and highlights potential therapeutic approaches.
Research
Researchers develop clinical decision tool for GA treatment
Atrophy Advisor could help clinicians determine the optimal therapeutic approach for GA patients.
Pipeline
Complement Therapeutics secures Fast Track Designation for lead GA therapy
AAV-based CTx001 modulates multiple pathways of the complement system when delivered as a one-time, subretinal injection.
Pipeline
Aviceda releases phase 2b topline data on AVD-104 for GA
Latest SIGLEC trial results show both dosing arms with 31% to 38% less lesion growth than prior trials; phase 3 plans are underway.
Pipeline
SeaBeLife and Unither to formulate and develop retinal degenerative disorder formulation
Collaboration focuses on accelerating development of SBL03, formulated for topical delivery to target retinal cell necrosis in GA and dry AMD.
Research
New 5-year Syfovre data indicates extended delay of GA progression
GALE extension study findings show delayed GA lesion growth by an estimated 1.5 years in patients receiving continuous treatment.
Pipeline
Complement Therapeutics' GA gene therapy IND receives FDA clearance
Clearance gives green light to begin Q1 2026 patient enrollment for the Opti-GAIN study evaluating CTx001 as a one-time, durable treatment.
Research
Real-world data support IZERVAY's long-term benefits
OLE trial of the GATHER2 study finds continued GA lesion growth for up to 3.5 years—with earlier intervention offering greater protection of the retinal tissue.
Pipeline
FDA grants Sanofi Fast Track designation for GA gene therapy
Status gives expedited pathway toward regulatory approval for SAR446597, designed as a one-time injection that blocks two of the three complement system pathways.
Pipeline
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant
Also under clinical development for Stargardt disease, the once-daily tablet is under evaluation for its efficacy in slowing atrophic lesion growth.
Pipeline
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.Products
FDA approves updated label for IZERVAY to treat GA
Astellas’s avacincaptad pegol now has no limitation on its dosing duration, enabling longer-term administration for patients with GA secondary to AMD.
Business
Bausch + Lomb adds to glaucoma and GA pipeline with two deals
Latest developments involve the acquisition of WhiteCap Biosciences and its GA candidate, as well as a partnership with RNAi-focused City Therapeutics.Products
FDA accepts revised sNDA of IZERVAY for GA
Company is requesting inclusion of 24-month data to extend approved dosage for an additional 12 months for both every-month and every-other-month dosing.
Business
Aviceda raises $207M to support phase 3 testing of AVD-104 for GA
Financing will support advancement of AVD-104, designed to target a specific area of the innate immune response relating to AMD.
Business
Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements
Newly-combined Tenpoint Therapeutics, Ltd includes a pipeline featuring BRIMOCHOL PF, a once-daily eye drop for presbyopia targeting an NDA filing in 2025.Products
FDA issues company response letter to Astellas for IZERVAY supplemental NDA
Agency rejects proposal for positive 24-month data to be included in prescribing information; clarifies no issue with safety and benefit/risk of use.
Pipeline
Despite missing primary outcomes, Alkeus' phase 3 GA trial shows promise
Oral gildeuretinol's clinically meaningful reduction in GA lesion growth warrants further clinical development, company says.
Research
Lampalizumab injections lead to low IOP risk for GA
A recent study examined the IOP safety of intravitreal lampalizumab and the rate of ocular adverse events.
Pipeline